Roche Holding, maker of the antiviral Tamiflu, said it agrees with studies suggesting a stronger dosage of the drug, a longer treatment period and combination with other antivirals may be needed in treating the H5N1 bird flu virus to account for possible resistance. But the company said countries should not stop stockpiling the drug based on the concerns, adding that a pandemic strain's emergence would be the time to test Tamiflu for the optimal dose and duration.

Related Summaries